[go: up one dir, main page]

SV2004001429A - Combinacion farmaceutica ref.pcs22057 - Google Patents

Combinacion farmaceutica ref.pcs22057

Info

Publication number
SV2004001429A
SV2004001429A SV2002001429A SV2002001429A SV2004001429A SV 2004001429 A SV2004001429 A SV 2004001429A SV 2002001429 A SV2002001429 A SV 2002001429A SV 2002001429 A SV2002001429 A SV 2002001429A SV 2004001429 A SV2004001429 A SV 2004001429A
Authority
SV
El Salvador
Prior art keywords
pcs22057
pharmaceutical combination
ref
combination ref
receiver agonist
Prior art date
Application number
SV2002001429A
Other languages
English (en)
Inventor
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SV2004001429A publication Critical patent/SV2004001429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMBINACION QUE COMPRENDE (A)UN AGONISTA DEL RECEPTOR DE ADENOSINA A2A COMO SE DEFINE EN LA PRESENTE MEMORIA (B) UN AGONISTA DEL REEPTOR ß2-ADRENERGICO, PARA LA ADMINISTRACION SIMULTANEA, SECUENCIAL O POR SEPARADO POR VIA INHALADA EN EL TRATAMIENTO DE UNA ENFERMEDAD OBSTRUCTIVA DE LAS VIAS RESPIRATORIAS U OTRA ENFERMEDAD INFLAMATORIA.
SV2002001429A 2001-12-07 2002-12-06 Combinacion farmaceutica ref.pcs22057 SV2004001429A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129397.6A GB0129397D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SV2004001429A true SV2004001429A (es) 2004-05-07

Family

ID=9927249

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001429A SV2004001429A (es) 2001-12-07 2002-12-06 Combinacion farmaceutica ref.pcs22057

Country Status (12)

Country Link
US (1) US20030109485A1 (es)
AR (1) AR037709A1 (es)
AU (1) AU2002347532A1 (es)
GB (1) GB0129397D0 (es)
GT (1) GT200200261A (es)
HN (1) HN2002000355A (es)
PA (1) PA8560401A1 (es)
PE (1) PE20030835A1 (es)
SV (1) SV2004001429A (es)
TW (1) TW200303754A (es)
UY (1) UY27565A1 (es)
WO (1) WO2003047628A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547636A1 (en) * 1995-04-14 2005-06-29 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
GT200200261A (es) 2003-07-11
TW200303754A (en) 2003-09-16
PA8560401A1 (es) 2003-12-10
US20030109485A1 (en) 2003-06-12
WO2003047628A1 (en) 2003-06-12
HN2002000355A (es) 2003-02-21
UY27565A1 (es) 2003-07-31
GB0129397D0 (en) 2002-01-30
AR037709A1 (es) 2004-12-01
AU2002347532A1 (en) 2003-06-17
PE20030835A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
PA8546101A1 (es) Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
CR9749A (es) Derivados de xantina como agonistas de hm74a selectivos
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
ECSP099250A (es) USO DE 2-6-(3-amino-piperidin-1-Il)-3-metil-2,4-dioxo-3,4-dihIdro-2H-pIrimidin-1-IlmetIL-4-fluoro-benzonitrilo
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
CY1109476T1 (el) Μεθοδος θεραπειας αθηροσκληρωσης δυσλιπιδαιμιων και σχετικων παθησεων και φαρμακευτικες συνθεσεις
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
HN2009000018A (es) Inhibidores de tirosina quinasa
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
AR055123A1 (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta, composicion farmaceutica que la contiene y su aplicacin en terapeutica
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
TW200642704A (en) Oral drug delivery system and methods of use thereof
SV2004001426A (es) Combinacion farmaceutica ref.pcs22049
SV2004001429A (es) Combinacion farmaceutica ref.pcs22057
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
PA8560601A1 (es) Combinacion farmaceutica
ATE389402T1 (de) Sedierende nicht-benzodiazepin-formulierungen
DOP2002000514A (es) Combinacion farmaceutica.

Legal Events

Date Code Title Description
FD Lapse